Moreover, the activation of the cGAS-STING pathway in sarcoma cells spared by the trabectedin-olaparib combination upregulates the NK/CIK activating ligand expression, as shown by functional assays after IRF3 silencing or direct IFNβ treatment, adding further insights into the complex regulation of the crosstalk between innate immunity and cancer [20–22, 68]. This evidence concerns the gene CGAS and sarcoma.